Vaccine Targeting KRAS in Pancreatic and Colorectal Cancer …
WEBFeb 1, 2024 — The new vaccine is able to activate immune cells that target different KRAS mutations called KRAS -G12D and KRAS -G12R, which drive about 90% of pancreatic cancers and 40% of colon cancers.
Quanta Announces IND Clearance by U.S. FDA for QTX3034,
WEBThe QTX3034 Phase 1 clinical trial will initially enroll patients with KRAS G12D mutations in dose escalation cohorts as monotherapy and in combination with cetuximab. Dose expansion cohorts ...
Sotorasib is First KRAS Inhibitor Approved by FDA - NCI
WEBJun 25, 2021 — FDA has approved the first KRAS-blocking drug, called sotorasib (Lumakras). The approval, which covers the use of sotorasib for some patients with advanced lung cancer, was based on the results of the CodeBreak100 trial.
FDA Approves First Targeted Therapy for Lung Cancer Mutation …
WEBMay 28, 2021. Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific...
Potential Drug Shows Promise Targeting a Range of KRAS-Driven …
WEBMay 31, 2023 — MSK investigators report exciting results for a new molecule that can block 16 different mutated forms of the KRAS protein. In the lab, the compound was effective against many cancer cell lines and in mouse models of lung cancer and colorectal cancer.
MRTX1133 Targets Tumors with KRAS G12D Mutations - NCI
WEBThe new drug, known as MRTX1133, shrank tumors or halted their growth in several mouse models of human pancreatic cancer with KRAS G12D mutations, including a genetically engineered mouse model known as KPC that closely mimics the human disease.
FDA grants accelerated approval to adagrasib for KRAS G12C …
WEBOn December 12, 2022, the Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, for adult patients with...
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of …
WEBDec 12, 2022 — KRAZATI is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who...
The KRAS crowd targets its next cancer mutations - Nature
WEBJan 23, 2023 — Clinic-ready inhibitors, degraders and molecular glues are pushing cancer frontiers by targeting KRAS variants including KRAS-G12D.
WEBBy Asher Mullard. Clinic-ready inhibitors, degraders and molecular glues are pushing cancer frontiers by targeting KRAS variants including KRAS-G12D. targets have undergone as dramatic a...